Tic disorder

B.More Receives FDA Investigational New Drug Approval for Psilocybin Alcohol Use Disorder Program Phase 2b Clinical Trial

Retrieved on: 
Thursday, August 25, 2022

Led by principal investigator, Michael Bogenschutz, Director of the NYU Langone Center for Psychedelic Medicine, the trial will be initiated in early 2023.

Key Points: 
  • Led by principal investigator, Michael Bogenschutz, Director of the NYU Langone Center for Psychedelic Medicine, the trial will be initiated in early 2023.
  • "Given the amazing results of the psilocybin for AUD Phase 2a trial that our principal investigator, Dr. Bogenschutz, just published in JAMA Psychiatry , we are thrilled to have received FDA approval to begin our Phase 2b trial", said Carey Turnbull, co-founder and CEO of B.More.
  • B.More's, randomized, double blind, active placebo-controlled, multicenter, Phase 2b trial will assess the efficacy and safety of synthetic psilocybin (SYNP-101) in treating moderate to severe AUD.
  • Efficacy of treatment will be assessed using changes in alcohol consumption as measured by World Health Organization Risk Drinking Levels Measure of Alcohol Consumption.

B.More Receives FDA Investigational New Drug Approval for Psilocybin Alcohol Use Disorder Program Phase 2b Clinical Trial

Retrieved on: 
Thursday, August 25, 2022

Led by principal investigator, Michael Bogenschutz, Director of the NYU Langone Center for Psychedelic Medicine, the trial will be initiated in early 2023.

Key Points: 
  • Led by principal investigator, Michael Bogenschutz, Director of the NYU Langone Center for Psychedelic Medicine, the trial will be initiated in early 2023.
  • "Given the amazing results of the psilocybin for AUD Phase 2a trial that our principal investigator, Dr. Bogenschutz, just published in JAMA Psychiatry , we are thrilled to have received FDA approval to begin our Phase 2b trial", said Carey Turnbull, co-founder and CEO of B.More.
  • B.More's, randomized, double blind, active placebo-controlled, multicenter, Phase 2b trial will assess the efficacy and safety of synthetic psilocybin (SYNP-101) in treating moderate to severe AUD.
  • Efficacy of treatment will be assessed using changes in alcohol consumption as measured by World Health Organization Risk Drinking Levels Measure of Alcohol Consumption.

Empire BlueCross BlueShield Announces Four New Partnerships to Address Behavioral Healthcare Needs in New York

Retrieved on: 
Tuesday, August 23, 2022

Today, Empire BlueCross BlueShield (Empire) is announcing a suite of innovative companies that are joining the Empire provider network as the company works to respond to the growing needs for behavioral healthcare services in New York.

Key Points: 
  • Today, Empire BlueCross BlueShield (Empire) is announcing a suite of innovative companies that are joining the Empire provider network as the company works to respond to the growing needs for behavioral healthcare services in New York.
  • Were excited to be entering a partnership with Empire BlueCross BlueShield to increase access to diverse, equitable, and affordable mental healthcare for New Yorkers, said Harry Ritter, founder and CEO, Alma.
  • Since launching with Empire in June 2022, more than 5,300 Empire members have received mental healthcare through Headway, with the average time to care just 5.9 days.
  • Serving New Yorkers for more than 85 years, Empire BlueCross BlueShield (Empire) is on a mission to materially and measurably improve the health of New Yorkers.

Indiana Center for Recovery Unveils BrainsWay Deep TMS™

Retrieved on: 
Tuesday, August 16, 2022

SOUTH BEND, Ind., Aug. 16, 2022 /PRNewswire/ -- Indiana Center for Recovery—the largest mental health and addiction treatment provider in the state—announces its partnership with BrainsWay, a leader in noninvasive neurostimulation treatments for mental health disorders. This technology, combined with custom care plans from Indiana Center for Recovery, will bring recovery and relief through clinically demonstrated, painless treatments that can be highly effective when other treatment modes have failed.

Key Points: 
  • BrainsWay's Deep TMS treatment is based on novel breakthrough technology that targets brain areas for increased stimulation and activity.
  • Boosting care for patients with substance use and mental health disorders, Indiana Center for Recovery will use Deep TMS within holistic treatment paths unique to each patient.
  • New patients will see how Indiana Center for Recovery's experts and compassionate professionals use Deep TMS to promote true wellness in South Bend and beyond.
  • Since 2016, Indiana Center For Recovery has pushed patient outcomes through expert staff, high-end facilities, and scientifically sound protocols for patient-centered recovery.

Addressing an Urgent Housing Need in Brooklyn: Regions Bank Arranges Vital Financing for New Housing

Retrieved on: 
Monday, August 15, 2022

The initiative is led by HELP USA , a national housing nonprofit dedicated to addressing the holistic needs of individuals and families experiencing homelessness.

Key Points: 
  • The initiative is led by HELP USA , a national housing nonprofit dedicated to addressing the holistic needs of individuals and families experiencing homelessness.
  • Regions Affordable Housing Division supported the development by arranging $62 million in equity, provided by BNY Mellon.
  • The development will help meet the need for both housing and social services for people impacted by chronic homelessness.
  • Regions Affordable Housing LLC is a national Low-Income Housing Tax Credit (LIHTC) investor, syndication firm, and leader in affordable housing.

The Recovery Team Launches BrainsWay Deep TMS™

Retrieved on: 
Monday, August 15, 2022

DELRAY BEACH, Fla., Aug. 15, 2022 /PRNewswire/ -- The Recovery Team—an evidence-based treatment center—debuts a partnership with BrainsWay, a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The partnership and technology will bring relief and recovery through clinically supported Deep Transcranial Magnetic Stimulation (Deep TMS™).

Key Points: 
  • The partnership and technology will bring relief and recovery through clinically supported Deep Transcranial Magnetic Stimulation (Deep TMS).
  • Enhancing care for patients with substance use and mental health disorders, Deep TMS will complement holistic treatment paths unique to each patient at The Recovery Team.
  • New patients will see how The Recovery Team's compassionate professionals use Deep TMS to advance wellness in South Florida beyond the usual limits.
  • The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives.

Artificial Intelligence In Drug Discovery Global Market Report 2022: Rise in Demand for a Reduction in the Overall Time Taken for the Drug Discovery Process is a Key Driver Propelling Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 11, 2022

The artificial intelligence (AI) in drug discovery market consists of sales of AI for drug discovery and related services.

Key Points: 
  • The artificial intelligence (AI) in drug discovery market consists of sales of AI for drug discovery and related services.
  • Artificial Intelligence (AI) for drug discovery is a technology that uses a simulation of human intelligence process by machines to tackle complex problems in the drug discovery process.
  • The rise in demand for a reduction in the overall time taken for the drug discovery process is a key driver propelling the growth of the artificial intelligence (AI) in drug discovery market.
  • The reduction in overall time taken for the drug discovery process drives the artificial intelligence (AI) in drug discovery market's growth.

NOCD Accepts AETNA Insurance Rapidly Expanding National Access For 16.5 Million Americans

Retrieved on: 
Tuesday, August 9, 2022

Today, NOCD, the worlds leading provider of obsessive-compulsive disorder (OCD) treatment, announces it now accepts Aetna Insurance, expanding access to NOCD Therapy for approximately 16 million more people in the United States.

Key Points: 
  • Today, NOCD, the worlds leading provider of obsessive-compulsive disorder (OCD) treatment, announces it now accepts Aetna Insurance, expanding access to NOCD Therapy for approximately 16 million more people in the United States.
  • NOCD is making exposure and response prevention (ERP) therapy, the gold-standard treatment for OCD, more effective, convenient, and affordable.
  • Inside the NOCD platform, members can receive ongoing, face-to-face teletherapy sessions from licensed NOCD Therapists who specialize in OCD treatment.
  • With the inclusion of Aetna, we now are partners with every national health plan, making us one step closer to our goal of ERP access for all.

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, August 5, 2022

In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Neuronetics Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.

Key Points: 
  • In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Neuronetics Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
  • The RSUs are subject to the terms of the Neuronetics 2020 Inducement Plan.
  • Neuronetics is committed to transforming lives by offering an exceptional treatment option that produces extraordinary results.
  • These forward-looking statements are based on the Companys expectations and assumptions as of the date of this press release.

Neuronetics Reports Second Quarter 2022 Financial and Operating Results

Retrieved on: 
Tuesday, August 2, 2022

In the second quarter of 2022, U.S. treatment session revenue per active site was $11,280 as compared to $12,001 during the second quarter of 2021 as a result of an increase in the number of new accounts installing systems in the second quarter of 2022.

Key Points: 
  • In the second quarter of 2022, U.S. treatment session revenue per active site was $11,280 as compared to $12,001 during the second quarter of 2021 as a result of an increase in the number of new accounts installing systems in the second quarter of 2022.
  • Gross margin for the second quarter of 2022 was 75.3%, a decrease of approximately 530 basis points from the second quarter of 2021 gross margin of 80.6%.
  • Operating expenses during the second quarter of 2022 were $22.1 million, an increase of $4.1 million, or 23%, compared to $18.0 million in the second quarter of 2021.
  • EBITDA for the second quarter of 2022 was $(9.1) million as compared to the second quarter of 2021 EBITDA of $(6.3) million.